| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2024-10-04 |
| タイトル |
|
|
タイトル |
Low-frequency CD8+ T cells induced by SIGN-R1+ macrophage-targeted vaccine confer SARS-CoV-2 clearance in mice |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Muraoka, Daisuke
Moi, Meng Ling
Muto, Osamu
Nakatsukasa, Takaaki
Deng, Situo
Takashima, Chieko
Yamaguchi Rui
Sawada, Shin-ichi
Hayakawa, Haruka
Nguyen, Thi Thanh Ngan
Haseda, Yasunari
Soga, Takatoshi
Matsushita, Hirokazu
Ikeda, Hiroaki
Akiyoshi, Kazunari
Harada, Naozumi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Vaccine-induced T cells and neutralizing antibodies are essential for protection against SARS-CoV-2. Previously, we demonstrated that an antigen delivery system, pullulan nanogel (PNG), delivers vaccine antigen to lymph node medullary macrophages and thereby enhances the induction of specific CD8+ T cells. In this study, we revealed that medullary macrophage-selective delivery by PNG depends on its binding to a C-type lectin SIGN-R1. In a K18-hACE2 mouse model of SARS-CoV-2 infection, vaccination with a PNG-encapsulated receptor-binding domain of spike protein decreased the viral load and prolonged the survival in the CD8+ T cell- and B cell-dependent manners. T cell receptor repertoire analysis revealed that although the vaccine induced T cells at various frequencies, low-frequency specific T cells mainly promoted virus clearance. Thus, the induction of specific CD8+ T cells that respond quickly to viral infection, even at low frequencies, is important for vaccine efficacy and can be achieved by SIGN-R1+ medullary macrophage-targeted antigen delivery. |
|
言語 |
en |
| 書誌情報 |
en : npj Vaccines
巻 9,
号 1,
p. art. no. 173,
発行日 2024-09-18
|
| 出版者 |
|
|
出版者 |
Springer Nature |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2059-0105 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1038/s41541-024-00961-6 |
| 権利 |
|
|
言語 |
en |
|
権利情報 |
This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by- nc-nd/4.0/. © The Author(s) 2024 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
npj Vaccines, 9(1), art. no. 173; 2024 |
|
言語 |
en |
NPJV9_173.pdf (3.9 MB)
